Show simple item record

dc.contributor.authorBaka, Sofia
dc.contributor.authorClamp, Andrew R
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-07-07T15:16:35Z
dc.date.available2009-07-07T15:16:35Z
dc.date.issued2006-12
dc.identifier.citationA review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. 2006, 10 (6):867-76 Expert Opin. Ther. Targetsen
dc.identifier.issn1744-7631
dc.identifier.pmid17105373
dc.identifier.doi10.1517/14728222.10.6.867
dc.identifier.urihttp://hdl.handle.net/10541/72854
dc.description.abstractAngiogenesis plays an important role in the formation of new blood vessels and is crucial for tumour development and progression. Imbalance between pro- and antiangiogenesis factors regulates the biological process of angiogenesis. The best characterised of the proangiogenic factors and the most potent is vascular endothelial growth factor (VEGF). The binding of VEGF to one of its transmembrane tyrosine kinase receptors, which are predominantly found on endothelial cells, results in receptor dimerisation, activation and autophosphorylation of the tyrosine kinase domain. This triggers a cascade of complex downstream signalling pathways. Several strategies targeting the VEGF signalling pathway have been developed. These include neutralising antibodies to VEGF (bevacizumab) or VEGF receptors (VEGFRs) (DC101), soluble VEGFR/VEGFR hybrids (VEGF-Trap), and tyrosine kinase inhibitors of VEGFRs (BAY43-9006, SU11248, ZD6474, AZD2171, PTK/ZK and others). Several of these agents are now being investigated in clinical trials.
dc.language.isoenen
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshClinical Trials as Topic
dc.subject.meshHumans
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshVascular Endothelial Growth Factors
dc.titleA review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Manchester, M20 4BX, UK. bakasofia@hotmail.comen
dc.identifier.journalExpert Opinion on Therapeutic Targetsen
html.description.abstractAngiogenesis plays an important role in the formation of new blood vessels and is crucial for tumour development and progression. Imbalance between pro- and antiangiogenesis factors regulates the biological process of angiogenesis. The best characterised of the proangiogenic factors and the most potent is vascular endothelial growth factor (VEGF). The binding of VEGF to one of its transmembrane tyrosine kinase receptors, which are predominantly found on endothelial cells, results in receptor dimerisation, activation and autophosphorylation of the tyrosine kinase domain. This triggers a cascade of complex downstream signalling pathways. Several strategies targeting the VEGF signalling pathway have been developed. These include neutralising antibodies to VEGF (bevacizumab) or VEGF receptors (VEGFRs) (DC101), soluble VEGFR/VEGFR hybrids (VEGF-Trap), and tyrosine kinase inhibitors of VEGFRs (BAY43-9006, SU11248, ZD6474, AZD2171, PTK/ZK and others). Several of these agents are now being investigated in clinical trials.


This item appears in the following Collection(s)

Show simple item record